Work overview

Section 07 of 07

Learning points

Continuation of burosumab during pregnancy in a patient with X-linked hypophosphatemia

Atsushi Suzuki, Yoshinori Moriyama, Haruo Mizuno, and Haruki Nishizawa · 2026

Contents

Section 07 of 07

  1. 01Introduction
  2. 02Case presentation
  3. 03Diagnostic assessment
  4. 04Treatment
  5. 05Outcome and follow-up
  6. 06Discussion
  7. 07Learning points
Text size
Work overview

Section 7 of 7

Learning points

Atsushi Suzuki, Yoshinori Moriyama, Haruo Mizuno, and Haruki Nishizawa · about 2 minutes

Original source ↗

  • Burosumab effectively improves pain and mobility in adults with XLH, and its continued use during pregnancy may be considered when the risk of symptomatic rebound is high.
  • Transplacental transfer of burosumab can result in markedly elevated serum FGF23 levels in the neonates, most likely due to antibody-antigen complex stability.
  • In this case, the infant's FGF23 levels dropped significantly by 3 months of age but remained elevated due to inherited XLH; no adverse skeletal events or developmental delay were observed at 1 year after switching to burosumab therapy.